Heart drug co. Relypsa gets $10M more to complete trials
Pharmaceutical company Relypsa announced that its investors extended its first round of funding by $10 million to a total $43 million to help it finish phase-two clinical trials on its lead drug candidate, a treatment that could alleviate symptoms of heart failure and chronic kidney… Continue Reading
Amgen, Relypsa and the art of the biotech-spinout-startup-restart
(UPDATED: See below.)
A common dilemma in biotech acquisitions is how to keep a startup’s entrepreneurial management happy and productive when they’ve just been assimilated by the Borg. The answer, often enough, is not to bother, and to let them spin out a new company with scientific… Continue Reading
Funding roundup: Announcements that got away
Although I try to stay on top of events in the life sciences, announcements do sometimes manage to slip through the cracks. Some days, in fact, I end up triaging. Because the roots of this site — not to mention many of its readers —… Continue Reading
Roxro Pharma gets $21.65M commitment for pain management
Roxro Pharma, a Menlo Park developer of drugs for acute pain management, has won $21.65 million more in commitments to extend its second round of funding, VentureWire reports (sub required).
The financing came from the company’s existing Series B investors: Prospect Ventures, Sutter Hill Ventures, Thomas… Continue Reading